Repurposing of androgen receptors inhibitors for prostate cancer treatment to treat other cancer in males such as melanoma.
This invention describes construction and initial functional testing of engineered chimeric antigen receptors transduced into human T-cells (CAR-T cells) for selective killing of melanocytes and melanoma cells.